Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

被引：0
|
作者：
Carter, Bing Z.
Mak, Po Yee
Ruvolo, Vivian
Tao, Wenjing
Hughes, Paul
Chen, Xiaoyue
Morrow, P. K.
Andreeff, Michael
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141399
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells
    Carter, Bing Z.
    Tao, Wenjing
    Mak, Po Yee
    Zhang, Qi
    Wang, Xiangmeng
    Kuruvilla, Vinitha Mary
    Stewart, Carli
    Ruvolo, Vivian
    Battula, Venkata Lokesh
    Konopleva, Marina Y.
    Caenepeel, Sean
    Canon, Jude
    Hughes, Paul
    Morrow, P. K.
    Andreeff, Michael
    BLOOD, 2019, 134
  • [2] THE FLT3 INHIBITOR GILTERITINIB HAS ACTIVITY IN PATIENTS WITH AML
    不详
    CANCER DISCOVERY, 2017, 7 (08) : 794 - 794
  • [3] Gilteritinib: potent targeting of FLT3 mutations in AML
    Levis, Mark
    Perl, Alexander E.
    BLOOD ADVANCES, 2020, 4 (06) : 1178 - 1191
  • [4] ERAS-601, a potent inhibitor of SHP2, synergistically enhances the activity of a FLT3 inhibitor, gilteritinib, in FLT3-mutated AML tumor models
    Martin, Leenus
    Patel, Roopal
    Zhang, Jingchuan
    Nevarez, Robin
    Congdon, Taylor
    Brail, Les
    Shoemaker, Robert
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis
    K Kojima
    M Konopleva
    T Tsao
    M Andreeff
    H Ishida
    Y Shiotsu
    L Jin
    Y Tabe
    H Nakakuma
    Leukemia, 2010, 24 : 33 - 43
  • [6] Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis
    Kojima, K.
    Konopleva, M.
    Tsao, T.
    Andreeff, M.
    Ishida, H.
    Shiotsu, Y.
    Jin, L.
    Tabe, Y.
    Nakakuma, H.
    LEUKEMIA, 2010, 24 (01) : 33 - 43
  • [7] Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
    Tarver, Theodore C.
    Hill, Jason E.
    Rahmat, Leena
    Perl, Alexander E.
    Bahceci, Erkut
    Mori, Kenichi
    Smith, Catherine C.
    BLOOD ADVANCES, 2020, 4 (03) : 514 - 524
  • [8] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Masamichi Mori
    Naoki Kaneko
    Yoko Ueno
    Masaki Yamada
    Ruriko Tanaka
    Rika Saito
    Itsuro Shimada
    Kenichi Mori
    Sadao Kuromitsu
    Investigational New Drugs, 2017, 35 : 556 - 565
  • [9] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565
  • [10] Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3 Via Mcl-1/Noxa Axis
    Kojima, Kensuke
    Konopleva, Marina
    Tsao, Twee
    Andreeff, Michael
    Ishida, Hiroshi
    Shiotsu, Yukimasa
    Jin, Linhua
    Tabe, Yoko
    Nakakuma, Hideki
    BLOOD, 2009, 114 (22) : 1019 - 1019
12345